-
公开(公告)号：US20240002411A1
公开(公告)日：2024-01-04
申请号：US18249837
申请日：2021-10-14
Applicant: NIHON MEDI-PHYSICS CO., LTD.
Inventor： Hideaki TAKEMORI , Hiroaki ICHIKAWA , Minoru KAWATANI , Akihiro IZAWA , Tomoyuki IMAI
CPC classification number: C07F7/003 , A61K51/088 , A61K51/1096 , A61K51/0491
Abstract: The present invention relates to a method for producing a radioactive zirconium-labeled complex that can realize a high labeling index in a reaction between a radioactive zirconium ion and a ligand compound. The production method of the present invention includes a step of reacting a radioactive zirconium ion with a ligand compound in a reaction solution containing water to coordinate the radioactive zirconium ion. This step is performed in a state where the pH of the reaction solution is in an acidic region. The reaction solution does not contain an organic solvent but contains a water-soluble organic compound having one or two sulfo groups or carboxy groups in its structure, separately from the ligand compound.
-
公开(公告)号：US20230390425A1
公开(公告)日：2023-12-07
申请号：US18249220
申请日：2021-10-15
Applicant: NIHON MEDI-PHYSICS CO., LTD.
Inventor： Minoru KAWATANI , Takahisa HANADA , Gota TONOYA , Takuya TAKEDA
IPC: A61K51/10 , A61K33/244 , C07K16/32 , C07K7/08 , A61P35/00
CPC classification number: A61K51/1096 , A61K33/244 , C07K16/32 , C07K7/08 , A61P35/00 , A61K38/00
Abstract: A conjugate of an anti-HER2 antibody site-specifically modified with a peptide and a chelating agent. The chelating agent is chelated with a metal radionuclide, the peptide and the chelating agent are linked by a linker (L), and the linker (L) does not contain a thiourea bond. A radiopharmaceutical including the conjugate as an active ingredient.
-
Patent Agency Ranking
公开(公告)号：US20240207463A1
公开(公告)日：2024-06-27
申请号：US18553443
申请日：2022-03-31
Applicant: NIHON MEDI-PHYSICS CO., LTD.
Inventor： Minoru KAWATANI , Takahisa HANADA , Gota TONOYA , Takuya TAKEDA
CPC classification number: A61K51/1096 , A61P35/00
Abstract: A conjugate of an anti-epidermal growth factor receptor (EGFR) antibody site-specifically modified with a peptide and a chelating agent. The chelating agent is chelated with a metal radionuclide, the peptide and the chelating agent are linked by a linker (L), and the linker (L) does not contain a thiourea bond.
-
公开(公告)号：US20230248854A1
公开(公告)日：2023-08-10
申请号：US17769657
申请日：2020-10-16
Applicant: NIHON MEDI-PHYSICS CO., LTD.
Inventor： Akihiro IZAWA , Yu OGAWA , Hiroaki ICHIKAWA , Minoru KAWATANI , Hideaki TAKEMORI , Yuki OKUMURA
IPC: A61K51/10
CPC classification number: A61K51/10
Abstract: The production method of a radioactive metal-labeled antibody of the present invention includes a step of conducting a click reaction of a radioactive metal complex and an antibody site-specifically modified with a peptide to produce a radioactive metal-labeled antibody. The click reaction is performed between a first atomic group of the radioactive metal complex and a second atomic group directly or indirectly linked to the peptide. The second atomic group is an atomic group containing an azide group, or an atomic group containing trans-cyclooctene.
-
公开(公告)号：US20250090700A1
公开(公告)日：2025-03-20
申请号：US18575079
申请日：2022-06-30
Inventor： Takuya TAKEDA , Minoru KAWATANI , Gota TONOYA , Kentaro FUJIWARA , Shoutaro TSUJI
Abstract: The present invention provides a humanized antibody that binds to a HEG1 protein and a complex of the antibody and a radionuclide. According to the present invention, there is a complex including an antibody, and a radionuclide, in which the antibody is a humanized antibody capable of binding a human HEG1 protein expressed on mesothelioma cells.
-
公开(公告)号：US20240316228A1
公开(公告)日：2024-09-26
申请号：US18688001
申请日：2022-08-31
Applicant: NIHON MEDI-PHYSICS CO., LTD.
Inventor： Satoshi KISHIMOTO , Takuya TAKEDA , Yudai NARITA , Minoru KAWATANI , Akihiro IZAWA , Yuta TARUMIZU
CPC classification number: A61K51/1096 , A61P35/00
Abstract: Provided is a conjugate of a chelating agent chelated with a radionuclide and a deglycosylated antibody, where the chelating agent site-specifically modifies the Fc region of the aforementioned antibody via a linker. The conjugate shows increased accumulation in a tumor and decreased accumulation in normal tissues. These differences in accumulation are associated with a decrease in a risk of side effects.
-
公开(公告)号：US20240207464A1
公开(公告)日：2024-06-27
申请号：US18556527
申请日：2022-04-20
Applicant: NIHON MEDI-PHYSICS CO., LTD.
Inventor： Minoru KAWATANI , Fumiaki TAKENAKA , Takahisa HANADA , Gota TONOYA , Takuya TAKEDA
CPC classification number: A61K51/1096 , A61K51/1027 , A61P35/00
Abstract: A conjugate of an anti-CD20 antibody and a chelating agent. The chelating agent is chelated with a metal radionuclide, the anti-CD20 antibody and the chelating agent are linked by a linker (L), and the linker (L) does not contain a thiourea bond. A radiopharmaceutical containing the conjugate as an active ingredient.
-
-
-
-
-
-
Search Results
7
records
(took 0.015 seconds)
